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Summary Urinary drug metabolites were measured in 21 patients receiving ifosfamide by continuous infusion
over 3 days. Mean values for the proportion of drug excreted as parent compound, 2-dechloroethylifosfamide
(2-DC), 3-dechloroethylifosfamide (3-DC), carboxyifosfamide (CX) and ifosforamide mustard (IPM) were 19,
6, 10, 7 and 8% of dose respectively. The proportion of urinary drug products in the form of ifosfamide fell
considerably over the course of the 3 days. This was mirrored by an increase in the proportion of 2-DC, 3-DC
and CX. The proportion in the form of IPM, however, remained unchanged. With successive cycles the
amount of 2-DC and IPM increased by about 10% per course. A very wide variation in the amount of each
metabolite was reproducibly seen between patients, but no evidence for a genetic polymorphism was found.
Urinary dechloroethyl metabolites correlated positively with each other and negatively with CX. Although
autoinduction increases 'activation' of ifosfamide when given over 3 days, our evidence suggests that
competing metabolic pathways prevent an increase in the amount of active metabolite formed.
The oxazaphosphorine ifosfamide (IFOS) has been used in
the treatment of cancer for nearly two decades and has an
established role in the chemotherapy of lung, cervical and
testicular cancers, neuroblastoma, Ewing's sarcoma and soft-
tissue sarcomas. It is a prodrug entirely dependent on
metabolism for its activity (Connors et al., 1974; Sladek,
1988) (see Figure 1 for a summary of the metabolic path-
ways). Ifosfamide is converted to its active intermediate (4-
OH-IFOS) by the cytochrome P450 enzymes (Connors et al.,
1974). There is evidence for enzyme induction by repeated
administration (Nelson et al., 1976; Piazza et al., 1984;
Wagner & Drings, 1986; Lind et al., 1989; Lewis et al., 1990),
and this may alter the proportions of metabolites formed.
Toxicity is common and may be severe. Whereas some side-
effects - myelosuppression and alopecia - are related to the
tumoricidal metabolite ifosforamide mustard, other toxicities
appear to be due to other products. Bladder toxicity and
nephrotoxicity are almost certainly caused by acrolein (Brock
et al., 1981), formed in equimolar amounts with ifosforamide
mustard (Alarcon et al., 1972). The cause of the neurotoxi-
city seen following ifosfamide therapy is less certain, but it
may be related to chloroacetaldehyde formed during the loss
of the chloroethyl moieties (Norpoth, 1976; Goren et al.,
1986). This compound could also contribute to renal damage
(Skinner et al., 1993). The co-products of these pathways are
2-dechloro- and 3-dechloroifosfamide. Clearly, the efficacy
and toxicity of ifosfamide will relate to the activity of the
products of not only the above pathways, but also other
inactivating pathways, notably 4-keto ifosfamide and
carboxyifosfamide.
Despite its importance, there are very few quantitative data
on ifosfamide metabolism. The purpose of the present study
was to determine the patterns of excretion and amounts of
urinary metabolites during IFOS therapy both during single
treatment cycles and in the same patients undergoing
repetitive treatments.
Materials and methods
The parent drug, ifosfamide (IFOS), and its metabolites (2-
chloroethyl)-2-amino-tetrahydro-2-oxide-2H-1,3,2-oxazaphos-
phorine, (2 dechloroethylifosfamide, 2DC), 2-(2-chloroethyl)-
amino-tetrahydro-2-oxide-2H- 1,3,2-oxazaphosphorine, (3-
dechloroethylifosfamide 3DC), 3-[N,N'-bis(2-chloroethyl-
amino)phosphinyloxy] propanic acid (carboxyifosfamide,
CX) and N,N'-bis(2-chloroethyl)phosphorodiamidic acid
(isophosphoramide mustard, IPM) were all prepared, authen-
ticated and kindly given by Asta Medica (Frankfurt, Ger-
many). The keto metabolite, when seen in patients' urine,
was present in amounts near the limit of detection and so
these are not reported here.
Sodium acetate, potassium hydroxide and 4-(4-nitro-
benzyl)pyridine (NBP) were all obtained from Sigma.
Methanol and acetone for development of the NBP reagent
were analar grade, and organic solvents for thin-layer
chromatography (TLC) were high-performance liquid
chromatography (HPLC) grade from Rathburn Chemicals,
UK.
Samplepreparation and TLC
A combined thin-layer chromatography-photography-densi-
tometry method similar to that previously described (Boddy
& Idle, 1992) was used in all assays. XAD-2 Spe-Ed solid
phase extraction cartridges (500 mg 3 ml-', Laboratory
Impex, Teddington, UK) were washed with 3 ml of water,
3 ml of methanol and finally 3-5 ml of water. Aliquots of
1 ml of patient urine, diluted patient urine or normal diluted
urine containing authentic metabolites (internal controls)
were applied to the cartridges, which were then washed with
3-5 ml of water. The cartridges were thoroughly dried by
passing air through them and drug and metabolites were
eluted with 3 ml of methanol. The methanol extract was
evaporated to dryness using a Techne 'Dri-Block sample
concentrator' at 40'C and air. Dry samples were recon-
stituted in 70 il of methanol for TLC application.
Authentic standards in methanol (5-20fig) and 40 jil of
the reconstituted patient or control urine extracts were ap-
plied to 20 cm x 10 cm HPTLC plates (precoated glass-
backed silica gel 60, Merck, Germany) using a 'Linomat IV'
TLC sample applicator (Camag, Switzerland). The plates
were placed in glass tanks containing dichloromethane-
methanol-glacial acetic acid (90:7:1) as the mobile phase
and allowed to run the full height of the plate. After drying
the plates were run in a second mobile phase of dichloro-
methane-methanol-glacial acetic acid (90:60:1) to a height
of 2 cm. The plates were allowed to air dry and were sprayed
with 5% NBP in acetone - 0.2 M acetate buffer pH 4.6 (8:2,
v/v). After drying, the plates were resprayed and again
allowed to dry before being heated in an oven at 150°C.
Photography and densitometry
The metabolites were detected by dipping the plates into 3%
methanolic potassium hydroxide and appeared as blue spots
on the plate. The spots deteriorate on standing and a
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Figure 1 Metabolic pathways of ifosfamide.
polaroid photograph was taken within 10 s of their develop-
ment. The photographic equipment consisted of a Polaroid
MP4 Land camera. The film used was Polaroid type 55,
which produces a negative as well as a black and white print.
Densitometric measurements were carried out on the black
and white photographs using an LKB Ultrascan XL enhanced
laser densitometer, which produces a negative as well as a
black and white print. The resulting trace gives a series of
peaks corresponding to each of the metabolites. The value of
the integrated peaks given by the authentic metabolites in
methanol were used as a calibration curve and the concentra-
tion in patient samples determined from it. Urine-containing
standards (20 or 50jigml-') and patient control urine were
run on all TLC plates to give recovery values for each
metabolite.
Patients
Twenty-one patients (six women and 15 men) with various
malignancies receiving IFOS as part of combination
chemotherapy were studied. The majority of patients (14)
had Ewing's sarcoma/primitive neuroectodermal tumour
(PNET) and were being treated on a protocol (IVAD) in
which they received IFOS at 9 or 6gmm2 in combination
with vincristine and doxorubicin or actinomycin D. The
other patients had osteosarcoma, rhabdomyosarcoma or
adenocarcinoma and were given IFOS (6.6-9 gm-2) in com-
bination with doxorubicin or epirubicin. No patient received
prior or concurrent therapy with cisplatin. Three osteosar-
coma patients were treated with IFOS (4.5-9 gm-2) only.
All the patients received the IFOS as an infusion over 3 days
with mesna given as a uroprotector. Patients' urine was
collected in 8 hourly periods throughout infusion. Volumes
were noted and three 10 ml aliquots from each collection
were frozen immediately and stored at - 20C until assay.
Results
Stability and recovery
The recovery of CX and IPM was initially found to be very
low from normal volunteer urine to which metabolites had
been added. As patients receiving IFOS are heavily hydrated
the urine they pass is dilute and CX and IPM were easily
seen in extracts. Diluting normal volunteer urine and then
adding metabolites improved the recovery (see Table I). The
recoveries of the other metabolites were unaffected by the
dilution of the urine. The addition of mesna to a final
concentration of 100Igml1l in urine did not affect
recovery.
To determine the stability of the metabolites, urine to
which metabolites had been added was left at room tempera-
ture for 0, 4 and 24 h and at high, normal and low pH
(Table II). The recovery of CX and IPM metabolites
decreased at high and low pH and with 24 h storage, but was
unaffected by freezing and thawing. These results imply that,
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and analysed, or frozen, as soon as possible. The presence (at
concentration 100ILgml-') or absence of mesna did not
affect stability.
Overall metabolite excretion
Twenty-one patients were studied, each receiving one or
more cycles of IFOS. Twenty-three cycles in 12 patients
produced complete urinary collections over the 3 days. Table
III gives the mean, range and standard deviation for each
metabolite excreted over 3 days for these 23 cycles, expressed
as a percentage of the dose given. Figure 2 shows a scatter
plot of the same data. It is clear from this plot that there is
considerable inter-patient variation in the amount of each
metabolite excreted.
Change in metabolite production during treatment
Between the first and third days of the infusion the amount
of IFOS in the urine remained fairly constant, while the
amount of metabolites increased in quantity (Figure 3a).
Expressed as a proportion of total urinary drug products the
figure for IFOS decreased from 55% to 30%, while those for
2-DC, 3-DC and CX all increased (Figure 3b). Most notable
was the 3-fold increase in CX from 5% to 15% of urinary
drug products. The proportion in the form of IPM did not
change.
for this was available on five patients who, between them,
underwent a total of 15 cycles of treatment. The analysis was
used to fit five lines of a common slope to these data.
Significant effects were seen with CX (F= 5.41, d.f. = 1, 9,
P<0.05) and IPM (F= 8.07, d.f. = 1, 9, P<0.025) and the
effects corresponded to increases of 10.3% and 9.4% respec-
tively with successive cycles. In summary therefore, small but
significant increases in the fraction of drug converted to
2-DC and to IPM were seen with successive cycles.
To determine whether certain metabolites were formed
earlier with successive cycles, the amount excreted on day 3
less that on day 1 was calculated and divided by the mean of
the two. This fractional difference was calculated for the
parent drug and each of the four metabolites. Using the
analysis of covariance on five patients, having 16 cycles
between them, five lines of common slope were fitted, and
significant slopes were found for the case of IFOS (F = 9.9,
d.f. = 1, 10, P<0.025), 3-DC (F= 6.4, d.f. = 1, 10, P<0.05)
and CX (F= 9.6, d.f. = 1, 10, P<0.025). The slopes corre-
sponded to decreases in the fractional difference of 0.12, 0.10
and 0.23 respectively with successive courses. This implies
that these compounds appear in the urine progressively ear-
lier in successive cycles of treatment.
Variation between patients
The possibility of a polymorphic distribution in the popula-
tion for metabolic pathways was investigated using the data
Effect ofdose
The total amount of each metabolite excreted increased with
increasing dose of IFOS, but the proportion of each
metabolite was fairly constant (Figure 4). This implies that,
over the limited dose range used, none of the metabolic
pathways became saturated.
Changes with successive treatment cycles
An analysis of covariance was carried out, with the cycle
number as independent variable. The dependent variable was,
for a particular cycle, the total amount of parent drug or
metabolite excreted divided by the total dose. Information
Table I Recovery of CX and IPM added to blank urine
Urine recovery (%)
Metabolite Undiluted Diluted 1:10 Diluted 1:20
CX 21.7±7.7 41±8 43±7.7
IPM a 26 7.6 27 8
aUndetectable.
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Figure 2 Scattergram of metabolites excreted in the urine of
patients receiving ifosfamide. The results are expressed as a
percentage of administered dose. The data shown are from 23
complete urinary collections from 12 patients.
Table II Stability of IFOS and metabolites in urine at varying pH and storage time
Time at RT (h) IFOS 2-DC 3-DC CX IPM
and pH recovery (%) recovery (%) recovery (%) recovery (%) recovery (%)
0, 6-7 93±3 80±4 85±6 45±6 25±8
4, 6-7 93±3 80±4 85±6 45±6 25±8
24, 6-7 93±3 80±4 85±6 30±6 10±8
0, 2 93 3 a a a 20
0, 12 93±3 80±4 85±6 27 12
24, 12 a 80 4 85 6 20 10
F/T 93±3 80±4 85±6 45±6 25±8
aUndetectable. RT, room temperature; F/T, sample frozen and thawed twice prior to assay.
Table III Mean and range of excreted metabolite as a percentage of dose
Dose IFOS 2-DC 3-DC CX IPM
(gm-2) (%) (%) (%) (%) (%)
Mean 8.0 18.6 5.9 10.1 6.8 7.6
Range 3-9 7.6-34.0 0.75-13.7 4.3-19.9 0.09-19.1 0.95-22.7
s.d. ± 1.4 ± 6.2 + 3.2 ± 3.4 ± 5.0 ± 5.0
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from ten patients in whom there was information on more
than one course. Data from the first day were used here in
order to maximise the number of data points and to reduce
the effect of any within-cycle enzyme induction. No clear
evidence of polymorphism could be seen in these patients
(Figure 5). Although patient 20 had a reproducibly small
quantity of CX on the first day, data from the complete
collections showed (Figure 6) that this patient was able to
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produce normal amounts of this metabolite. Of the patients
with complete collections, patient 19, not depicted in Figure
5 as no replicate treatment was carried out, was strikingly
different from the others in that all metabolites were present
in high concentration compared with the parent drug (Figure
6). This patient had not been taking any known inducing
agents.
Correlations between metabolites
Analysis was confined to data from 13 patients with complete
collections. Where more than one cycle was available means
were taken over all cycles. When the variables were taken to
be the amount of metabolite or parent drug as a proportion
of dose, positive correlations were found between almost all
of them. This may merely reflect variable collection of urine.
Therefore, for each patient the ratio of metabolite to parent
drug in the urine was taken. Patient 19 was clearly different
(Figure 6) and was excluded from the analysis. A significant
positive correlation was observed between the following pair
of ratios: 2-DC/IFOS vs 3-DC/IFOS (r = 0.70, d.f. = 10,
P <0.02). Significant negative correlations were observed
between the following pairs of ratios: 2-DC/IFOS vs CX/
IFOS (r =-0.69, d.f. = 10, P <0.02), 3-DC/IFOS vs CX/
IFOS (r =-0.71, d.f. = 10, P <0.02). In summary, this
implies that patients who convert more IFOS to 2-DC also
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Figure 4 Urinary drug or metabolite, collected over 3 days of
infusion, as a proportion of total dose and plotted against total
dose. Numbers in parentheses are the number of infusions. 0,
IFOS; A, 2-DC; 0, 3-DC; 0, CX; *, IPM.
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Figure 5 Urinary drug or metabolite as a percentage of total
measured urinary drug product during the first day of the
infusion. Mean and s.e. are shown for 10 patients who received
more than one cycle of treatment.
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Figure 6 Urinary metabolites as a fraction of urinary IFOS.
Data points from each of 13 patients are shown joined.
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tend to (a) convert more IFOS to 3-DC and (b) convert less
IFOS to CX.
The creatinine clearance was estimated for each patient
from their pretreatment serum creatinine by the method of
Cockroft and Gault (1976). No significant correlations were
found between any of the four ratios (metabolite/IFOS) and
the creatinine clearance.
Discussion
Clearly there are problems posed by the assay of ifosfamide
urinary metabolites. IPM and CX have been found to be
unstable when added to urine. The stability of these sub-
stances in the urine of patients who have received ifosfamide
therapy is an apparent paradox, the reason for which has not
yet been elucidated. Loss of IPM and CX due to breakdown
was minimised in our studies by collecting of urine in 8 h
increments and freezing aliquots within a few hours. The
time urine spent in the bladder in our patients would have
been short since the ifosfamide was administered with large
volumes of fluid. From the stability data in Table II our
estimates for maximum losses of CX and IPM due to break-
down are 15% and 25% respectively.
Another problem relates to the extraction. This was satis-
factory for ifosfamide and the dechloroethylated compounds
(85-93%), but it was only 45% for CX and 25% for IPM.
For this reason the extraction from urine of pure compounds
was determined with every assay, and inter-assay variability
was assessed by including the same clinical sample on each
occasion. Replicate assays were always carried out and,
where possible, data from repeat treatments have been
shown. In fact, our results for total urinary excretion of urine
metabolites are almost identical to those of Boddy and Idle
(1992), who used the same method. An earlier study found
only 9% of administered dose in the urine (Lind et al., 1990).
The amount of IPM measured in the urine will be smaller
than that formed as it is a reactive compound which forms
covalent bonds with macromolecules. The assumption is
made however that there will not be large differences in the
ratio between the amount retained and that lost in the urine
between individuals. Traditionally, studies on urine are
preferred to those on plasma when quantifying drug meta-
bolism. It should be noted however that Boddy et al. (1993)
found a discrepancy between plasma and urine estimation of
dechloroethylated metabolites.
In our patients 50% of the administered dose of IFOS was
measurable in the urine using the TLC/NBP assay. It is
probable that urinary metabolites were present. At least one
other, running close to the CX band, also gave a positive
stain with NBP, and this awaits identification. Malet-Martino
and Martino (1992), using 3"P-NMR, detected alcoifosfamide
in human urine, and this is very similar in structure to CX.
Also detected by them was another unidentified metabolite
and several breakdown products of known metabolites. No
attempt was made to detect NBP-negative metabolites.
Seventeen per cent of the measured products (8% of the
administered dose) were in the form of IPM. A 3-fold varia-
tion in this figure between patients was reproducibly seen on
the first day of treatment. This very large variability in the
amount of active metabolite produced may occasionally
account for poor drug activity.
IPM and CX are both products of 4-hydroxylation (Con-
nors et al., 1974). The sum of these two compounds is the
best available measure of hydroxylation activity. The forma-
tion of CX from the intermediate, aldoifosfamide, is an
inactivation step that diverts the compound from formation
of the active species. On the first day of treatment the
amount of CX as a fraction of CX + IPM is fairly small, but
by the third day it has increased considerably. It has been
shown (Figure 3b) that, whereas the proportion of urinary
drug products in the form of metabolites has increased
overall, this does not apply to IPM. This implies that induc-
tion of 4-hydroxylation is offset by increased activity of the
carboxylation. Further studies are required to determine how
the metabolism changes over 5 days, but the question is of
relevance. Lewis et al. (1990) found that the area under the
curve for plasma 'alkylating activity' (positive NBP test)
during a 5 day treatment increased more than 3-fold, while
the plasma half-life was reduced by 36%. As all the
metabolites described here give a positive NBP test, the
increase in plasma 'alkylating activity' may not represent an
increase in the amount of active species produced. Assuming
there was no influence of dose on metabolism, this would
mean that IFOS could be administered on one day only
without reduced efficacy.
Although large differences were seen in the pattern of
metabolite excretion during a cycle of treatment, only minor
differences were seen between cycles. There was a 9-10%
increase in the amounts of IPM and 2-DC per cycle, while
IFOS, 3-DC and CX tended to appear earlier in later cycles.
In the case of cyclophosphamide a polymorphism has been
suggested for the rate of carboxylation (Hadidi et al., 1988).
It is probable that the same enzyme gives rise to CX and a
bimodal distribution of the amount of CX formed might be
anticipated. Although we saw a similar variation in CX as
has been described for carboxyphosphamide, we cannot
discern a bimodal distribution from the present data. The
variability in the amount of CX produced on the first day,
expressed as a proportion of total drug products, was 15-
fold, and one patient reproducibly had a very low value.
However, since this patient showed a substantial increase in
the amount of CX produced by the third day, it seems
unlikely that the low value was related to a genetically deter-
mined deficiency of enzyme activity. We have seen a solitary
patient who produces abnormally large amounts not only of
CX, but of all measured metabolites. This remains unex-
plained and does not resemble one of the metabolic pheno-
types previously described.
The neurotoxicity of ifosfamide has been ascribed to chlor-
acetaldehyde released from dechlorethylation of ifosfamide
(Norpoth, 1976; Goren et al., 1986). It is of some interest
that there were reproducibly wide variations in the amounts
of dechlorometabolites appearing in the urine. That the pro-
portion of 2-DC and 3-DC in the urine increased over 3 days
of treatment indicates that this pathway is inducible, as has
recently been suggested by the observation that plasma
values of dechloroethyl metabolites increase in children over
the course of a 3 day infusion of ifosfamide (Boddy et al.,
1993). Whether this has a role in the generation of toxicity
remains to be established.
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